This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0272989X08318467v1 28/6/803    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Goldman, L. Articles by Gaspoz, J.-M. Search for Related Content PubMed PubMed Citation Articles by Goldman, L. Articles by Gaspoz, J.-M. Social Bookmarking                         What's this?

Cost-Effectiveness of Clopidogrel: Seeing through the Smoke

^* To whom correspondence should be addressed. E-mail: Jean-Michel.Gaspoz{at}hcuge.ch.

	Abstract

Background. A recent article in this journal raised specific questions about the authors’ methods for modeling the cost-effectiveness of clopidogrel for secondary prevention of coronary heart disease. The key issues raised were inclusion of incident cases, time horizon, and use of an inclusive model structure. Methods. The authors reviewed various recommendations and practices for cost-effectiveness analysis. They also performed a PubMed search for clopidogrel and cost-effectiveness from 2004 to early 2008 to obtain original analyses published in English to look for possible associations of assumptions and conclusions with reported pharmaceutical support. Results. Inclusion of incident cases and truncation at a sensible follow-up time more appropriately reflect the burden to be assumed by third-party payers. Extending the time horizon too far runs the risk of decreasing any relation with future reality. Parsimony cannot justify simplifications that omit relevant issues such as noncoronary costs, which worsen the calculated cost-effectiveness ratio of clopidogrel by 5% to 27%. The choice of the population to be analyzed has a major effect on cost-effectiveness: pharmaceutically sponsored studies published between 2004 and early 2008 focused on high-risk patients and have routinely shown more favorable cost-effectiveness ratios for clopidogrel than studies without pharmaceutical support. Conclusion. Any entity hoping to make the cost-effectiveness ratio of clopidogrel look more favorable would prefer the isolated, cohort approach and limit the analysis to high-risk patients most likely to benefit from it. This approach ignores the reality of medical policies and does not address the most relevant questions regarding the optimum use of clopidogrel. Key words: cost-effectiveness; antiplatelet drugs; models; pharmaceutical support (Med Decis Making XXXX;XX:xx–xx)

First published on June 12, 2008, doi:10.1177/0272989X08318467

Medical Decision Making 2008;28:803.

A more recent version of this article appeared on November 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?